{"entity":{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","aka":[],"tldr":"Where trastuzumab (Slamon) and palbociclib were developed clinically, and a leader in PSMA PET and melanoma immunotherapy (Ribas).","summary":"The UCLA Jonsson Comprehensive Cancer Center in Los Angeles holds NCI comprehensive designation and is where trastuzumab was developed clinically through Slamon's HER2 work, where palbociclib entered the clinic, and where Antoni Ribas built a leading melanoma immunotherapy programme in checkpoint and TIL research. Johannes Czernin and Jeremie Calais made it a centre for PSMA PET, Hurvitz ran its breast trials programme before moving to Fred Hutch, and Michael A. Teitell, Amar U. Kishan, Aditya Bardia, Denise R. Aberle and the patient Barbara Bradfield are also listed. OnCo links it to HER2 and PSMA as targets, to trastuzumab, palbociclib and gallium-68 PSMA-11, and to melanoma and prostate cancer. How to extend the HER2 model of target, drug and companion test to new targets remains its recurring theme. Its HER2, melanoma and PSMA programmes are the ones to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.uclahealth.org/cancer"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["psma-pet","mr-linac"],"targets":["her2","psma"],"drugs":["trastuzumab","palbociclib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["michael-teitell","antoni-ribas","johannes-czernin","jeremie-calais","amar-kishan","barbara-bradfield","richard-finn","aditya-bardia","denise-aberle","zev-wainberg","timothy-cloughesy","dennis-slamon","owen-witte"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Los Angeles","country":"US","lat":34.066,"lng":-118.446,"institutionType":"cancer-center","website":"https://www.uclahealth.org/cancer","nci":"comprehensive","university":"University of California, Los Angeles","programs":["HER2 (Slamon)","Melanoma immunotherapy (Ribas)","PSMA PET"]},"route":"/institutions/ucla-jonsson/","neighbours":{"technology":[{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"drug":[{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"person":[{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/"},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/"},{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/"},{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/"},{"id":"denise-aberle","kind":"person","name":"Denise R. Aberle","route":"/people/denise-aberle/"},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/"},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/"},{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/"},{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/"},{"id":"richard-finn","kind":"person","name":"Richard S. Finn","route":"/people/richard-finn/"},{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/"},{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","route":"/people/timothy-cloughesy/"},{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","route":"/people/zev-wainberg/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/"}],"paper":[{"id":"paper-psma-prerp-hope-jama-oncol-2021","kind":"paper","name":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","route":"/key-papers/paper-psma-prerp-hope-jama-oncol-2021/"},{"id":"paper-ribas-wolchok-checkpoint-blockade-science-2018","kind":"paper","name":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","route":"/key-papers/paper-ribas-wolchok-checkpoint-blockade-science-2018/"},{"id":"paper-slamon-her2-breast-ovarian-science-1989","kind":"paper","name":"Slamon 1989: HER2/neu in human breast and ovarian cancer","route":"/key-papers/paper-slamon-her2-breast-ovarian-science-1989/"},{"id":"paper-tumeh-pd1-adaptive-immune-resistance-nature-2014","kind":"paper","name":"Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge","route":"/key-papers/paper-tumeh-pd1-adaptive-immune-resistance-nature-2014/"}],"company":[{"id":"viewray","kind":"company","name":"ViewRay (MRIdian)","route":"/companies/viewray/"}],"trial":[{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/"}]}}